Completed PHASE2 INTERVENTIONAL 3-arm NCT01438489

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus

Sponsor: MedImmune LLC

Conditions Systemic Lupus Erythematosus

Interventions Anifrolumab 1000 mg Anifrolumab 300 mg Placebo

Updated 8 times since 2017 Last updated: Aug 29, 2016 Started: Jan 31, 2012 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Systemic Lupus Erythematosus, this trial is completed. The trial is conducted by MedImmune LLC and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Oct 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedImmune LLC

Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arequipa, Peru , Atlanta, United States , Barranquilla, Colombia , Bialystok, Poland , Birmingham, United States , Bogotá, Colombia , Brasov, Romania , Brno, Czechia , Bucaramanga, Colombia , Budapest, Hungary and 69 more locations